Home > News > Clinical Data Presented at ESMO
November 8th, 2004
Clinical Data Presented at ESMO
Abstract:
ACLARA BioSciences today announced that Sharat Singh, Ph.D., ACLARA's Chief Technical Officer, presented data from a pilot clinical trial demonstrating the ability of ACLARA's eTag(TM) assays to correctly differentiate responders from non-responders to Herceptin(R) treatment in patients with breast cancer. These data, subject to confirmation in larger, trials, suggest that the eTag System may be more accurate than the current standard at differentiating responders from non-responders to this widely used targeted therapy.
Source:
ACLARA BioSciences
Bookmark:
| Related News Press |
Possible Futures
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||